Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

‘Assuming’ OTC Narcan Approval, Emergent Notes Opportunity But Forecasts Full-Year Revenue Dip

Feb 28 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

Feb 13 2023

Naloxone Switch NDA Submitted As US FDA Signals Nonprescription Access Looks Safe, Effective

Nov 16 2022

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Nov 16 2022

Urgency For Approval Of OTC Naloxone In US Weighed Against Using Untested Package Labeling

Feb 16 2023

Related Companies

Emergent BioSolutions, Inc.

Additional Topics

International United States US States FDA Prescription To OTC Switch Sales & Earnings Advertising, Marketing & Sales Business Strategies Commercial Companies Clinical Trials Compliance Consumer Distribution Drug Approval Standards Drug Safety Ingredients Manufacturing Launches OTC Drugs OTC Devices Policy Regulation Retail Safety

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window